2014
Overview
Gynecologic cancer screening refers to the systematic testing of women, often without symptoms, to detect cancers of the female reproductive organs, including the cervix, uterus, ovaries, vagina, and vulva, at an early and more treatable stage. The best-established screening program is for cervical cancer, using cervical cytology (the Pap test) and testing for high-risk human papillomavirus (HPV), which together can identify precancerous changes before invasive disease develops. For other gynecologic cancers, such as ovarian and endometrial cancer, broad population screening is less established, and detection often relies on evaluating symptoms, risk factors, and family history. Early detection through screening is associated with improved prognosis and survival, because treatment is generally more effective when disease is found before it has spread. Screening strategies are informed by hematology and oncology research, which advances the understanding of how these cancers arise, how they can be identified, and how biomarkers may aid diagnosis and risk stratification, including work on molecular markers for rare uterine tumors. This page gathers peer-reviewed, open-access research relevant to gynecologic cancers and cancer biology within the broad scope of hematology and oncology research.
Research published in this journal
1 peer-reviewed article, ranked by relevance. Each links to its DOI.
How this research is being cited
The 1 article above has been cited 1 time in the scholarly literature. Citation data via OpenAlex and Crossref, updated Jun 2026.
-
2014 · Journal of Hematology and Oncology Research
A sample of recent works citing this journal's research on Gynecologic Cancer Screening, linking to each citing work.